SAGE Therapeutics (SAGE) Earns Buy Rating from Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of SAGE Therapeutics (NASDAQ:SAGE) in a report released on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $170.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on SAGE. Canaccord Genuity reiterated a buy rating and set a $220.00 price objective on shares of SAGE Therapeutics in a research report on Tuesday, June 12th. BidaskClub downgraded SAGE Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, June 19th. Stifel Nicolaus boosted their price objective on SAGE Therapeutics from $198.00 to $239.00 and gave the stock a buy rating in a research report on Tuesday, August 7th. Cowen reiterated a buy rating and set a $207.00 price objective on shares of SAGE Therapeutics in a research report on Thursday, June 14th. Finally, Piper Jaffray Companies began coverage on SAGE Therapeutics in a research report on Monday, August 6th. They set an overweight rating and a $206.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $204.50.

Shares of NASDAQ SAGE traded up $5.03 during midday trading on Wednesday, hitting $124.82. 389,900 shares of the company’s stock were exchanged, compared to its average volume of 495,274. The company has a market cap of $6.59 billion, a PE ratio of -17.61 and a beta of 2.92. SAGE Therapeutics has a twelve month low of $59.57 and a twelve month high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The business had revenue of $90.00 million for the quarter. As a group, equities research analysts forecast that SAGE Therapeutics will post -7.37 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Flinton Capital Management LLC lifted its position in SAGE Therapeutics by 1,900.0% in the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 646 shares during the period. US Bancorp DE increased its holdings in shares of SAGE Therapeutics by 5,593.3% in the second quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 839 shares in the last quarter. Creative Planning bought a new position in shares of SAGE Therapeutics in the second quarter valued at $210,000. Atria Investments LLC bought a new position in shares of SAGE Therapeutics in the second quarter valued at $218,000. Finally, Tiverton Asset Management LLC bought a new position in shares of SAGE Therapeutics in the second quarter valued at $229,000.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Beta

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply